{"transactions":[{"id":3596,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":1286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":15867,"derivative":{"exercise_price":24.2,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":1286},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3595,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":7999,"derivative":{"exercise_price":24.2,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3594,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":9012,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":620},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3593,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":false,"shares":694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":12824,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":694},"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3592,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":1286,"price":24.2,"value":31121.2,"ownership":{"direct":true},"balance_after":82962,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3591,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":24.2,"value":48400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":81676,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3590,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":620,"price":18.7,"value":11594.0,"ownership":{"direct":true},"balance_after":79676,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3589,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-02","kind":"exercise","planned":false,"acquired":true,"shares":694,"price":12.7,"value":8813.8,"ownership":{"direct":true},"balance_after":79056,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":3588,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:02:11.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":928,"price":47.5,"value":44080.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":78362,"source":{"system":"sec-edgar","filing":"0000905148-26-004080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509688/000090514826004080/form4.xml","form_type":"4"}},{"id":730909,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-22T20:11:57.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-26-003036","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003036/form4.xml","form_type":"4"}},{"id":752649,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":13518,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":2181},"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752648,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":1200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":9632,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752647,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":928,"price":29.86,"value":27710.08,"ownership":{"direct":true},"balance_after":78790,"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752646,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2181,"price":12.7,"value":27698.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":79718,"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":752645,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T22:03:50.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":1200,"price":18.7,"value":22440.0,"ownership":{"direct":true},"balance_after":77537,"source":{"system":"sec-edgar","filing":"0000905148-26-002811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002811/form4.xml","form_type":"4"}},{"id":894186,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:06:06.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":20636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026."}],"balance_after":76337,"source":{"system":"sec-edgar","filing":"0000905148-26-000952","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000952/form4.xml","form_type":"4"}},{"id":908104,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:50:22.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":3546,"price":34.62,"value":122762.52,"ownership":{"direct":true},"balance_after":55701,"source":{"system":"sec-edgar","filing":"0000905148-26-000678","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000678/form4.xml","form_type":"4"}},{"id":919908,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:21:11.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":5488,"price":36.01,"value":197622.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 500 shares acquired under the Issuer's stock purchase plan."}],"balance_after":59247,"source":{"system":"sec-edgar","filing":"0000905148-26-000497","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826000497/form4.xml","form_type":"4"}},{"id":958579,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":10832,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958578,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":2846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":17153,"derivative":{"exercise_price":24.2,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":2846},"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958577,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":false,"shares":1987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":14262,"derivative":{"exercise_price":20,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":1987},"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958576,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":1667,"price":18.7,"value":31172.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":64235,"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958575,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":2846,"price":24.2,"value":68873.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":62568,"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":958574,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T01:06:30.000Z","date":"2025-12-22","kind":"exercise","planned":false,"acquired":true,"shares":1987,"price":20,"value":39740.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 500 shares of common stock acquired under the Issuer's stock purchase plan."}],"balance_after":59722,"source":{"system":"sec-edgar","filing":"0000905148-25-004492","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825004492/form4.xml","form_type":"4"}},{"id":1038334,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-17T20:27:04.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":7394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met."}],"balance_after":7394,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":7394},"source":{"system":"sec-edgar","filing":"0000905148-25-003351","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825003351/form4.xml","form_type":"4"}},{"id":1197502,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:36.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":7850,"derivative":{"exercise_price":12.7,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000905148-25-000980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000980/form4.xml","form_type":"4"}},{"id":1197501,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-20T00:56:36.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":5625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met."}],"balance_after":5625,"derivative":{"exercise_price":35.4,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":5625},"source":{"system":"sec-edgar","filing":"0000905148-25-000980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000980/form4.xml","form_type":"4"}},{"id":1280587,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:22.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":1734,"price":21.926,"value":38019.684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":57235,"source":{"system":"sec-edgar","filing":"0000905148-25-000413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000413/form4.xml","form_type":"4"}},{"id":1280586,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:27:22.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":2036,"price":20.921,"value":42595.156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":58969,"source":{"system":"sec-edgar","filing":"0000905148-25-000413","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000413/form4.xml","form_type":"4"}},{"id":1289882,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-31T23:47:23.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":14788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period."}],"balance_after":14788,"derivative":{"exercise_price":22.49,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":14788},"source":{"system":"sec-edgar","filing":"0000905148-25-000300","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000300/form4.xml","form_type":"4"}},{"id":1289881,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-31T23:47:23.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":19717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 999 shares acquired under the Issuer's stock purchase plan."}],"balance_after":61005,"source":{"system":"sec-edgar","filing":"0000905148-25-000300","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825000300/form4.xml","form_type":"4"}},{"id":1351423,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-11-27T01:01:06.000Z","date":"2024-11-25","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met."}],"balance_after":6250,"derivative":{"exercise_price":18.7,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000905148-24-003281","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824003281/form4.xml","form_type":"4"}},{"id":1416286,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-09-05T00:33:43.000Z","date":"2024-08-30","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on August 30, 2024, the date the determination was made that the performance metric had been met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the \"Reverse Stock Split\"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met."}],"balance_after":10000,"derivative":{"exercise_price":24.2,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000905148-24-002511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824002511/form4.xml","form_type":"4"}},{"id":1607842,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-02T00:16:09.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":78500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was granted an option with a performance-based condition with respect to 78,500 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met."}],"balance_after":78500,"derivative":{"exercise_price":1.27,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":78500},"source":{"system":"sec-edgar","filing":"0000905148-24-000851","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000851/form4.xml","form_type":"4"}},{"id":1607841,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-02T00:16:09.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted an option with a performance-based condition with respect to 62,500 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met."}],"balance_after":62500,"derivative":{"exercise_price":1.87,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0000905148-24-000851","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000851/form4.xml","form_type":"4"}},{"id":1657179,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-07T01:18:43.000Z","date":"2024-02-05","kind":"sale","planned":false,"acquired":false,"shares":7027,"price":1.14,"value":8010.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":402891,"source":{"system":"sec-edgar","filing":"0000905148-24-000446","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000446/form4.xml","form_type":"4"}},{"id":1657178,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-07T01:18:43.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":5601,"price":1.1296,"value":6326.8896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $1.1228 to $1.13. Upon request, the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission staff, full information regarding the shares sold at each such separate price."}],"balance_after":409918,"source":{"system":"sec-edgar","filing":"0000905148-24-000446","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000446/form4.xml","form_type":"4"}},{"id":1671202,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-01-26T02:16:50.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":157000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period."}],"balance_after":157000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":157000},"source":{"system":"sec-edgar","filing":"0000905148-24-000306","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000306/form4.xml","form_type":"4"}},{"id":1671201,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-26T02:16:50.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":209000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 1, 2024, with the first annual vest occurring on February 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":415519,"source":{"system":"sec-edgar","filing":"0000905148-24-000306","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824000306/form4.xml","form_type":"4"}},{"id":2030962,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-06T22:40:54.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":5389,"price":1.6601,"value":8946.2789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such \"sales to cover\" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person."}],"balance_after":196519,"source":{"system":"sec-edgar","filing":"0001140361-23-004732","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123004732/form4.xml","form_type":"4"}},{"id":2042509,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T02:45:42.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period."}],"balance_after":125000,"derivative":{"exercise_price":1.87,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001140361-23-003441","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123003441/form4.xml","form_type":"4"}},{"id":2042508,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-31T02:45:42.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met."}],"balance_after":100000,"derivative":{"exercise_price":2.42,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-23-003441","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123003441/form4.xml","form_type":"4"}},{"id":2042507,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-31T02:45:42.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,000 shares acquired under the issuer's stock purchase plan."}],"balance_after":201908,"source":{"system":"sec-edgar","filing":"0001140361-23-003441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123003441/form4.xml","form_type":"4"}},{"id":2074456,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-12-30T21:30:41.000Z","date":"2022-12-28","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On December 28, 2022, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on December 28, 2022, the date the determination was made that the performance metric had been met."}],"balance_after":50000,"derivative":{"exercise_price":2.42,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-22-047668","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122047668/form4.xml","form_type":"4"}},{"id":2157618,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"officer":true,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-09-16T20:15:43.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted an option with a performance-based condition with respect to 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met."}],"balance_after":81250,"derivative":{"exercise_price":2,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":81250},"source":{"system":"sec-edgar","filing":"0001140361-22-033611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122033611/form4.xml","form_type":"4"}},{"id":2425466,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-27T01:47:18.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period."}],"balance_after":100000,"derivative":{"exercise_price":2.42,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-22-001782","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000156761922001782/doc1.xml","form_type":"4"}},{"id":2425465,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-27T01:47:18.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,908 shares acquired under the Issuer's stock purchase plan."}],"balance_after":128908,"source":{"system":"sec-edgar","filing":"0001567619-22-001782","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000156761922001782/doc1.xml","form_type":"4"}},{"id":2523327,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T23:06:33.000Z","date":"2021-11-04","kind":"grant","acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted a performance-based option to purchase 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on October 25, 2021, the date the performance metric had been met."}],"balance_after":81250,"derivative":{"exercise_price":2,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":81250},"source":{"system":"sec-edgar","filing":"0001567619-21-019430","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000156761921019430/doc1.xml","form_type":"4"}},{"id":2762076,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-02T22:23:06.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted a performance-based option to purchase 50,000 shares of common stock on February 6, 2020. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On April 1, 2021, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested on April 1, 2021, the date the performance metric had been met."}],"balance_after":50000,"derivative":{"exercise_price":2.42,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179110-21-004127","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021004127/edgar.xml","form_type":"4"}},{"id":2890670,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Stock Option(right to buy)","published_at":"2021-01-29T23:55:57.000Z","date":"2021-01-27","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2021, subject to the reporting person's continuous service to the issuer through each such period."}],"balance_after":112500,"derivative":{"exercise_price":3.54,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001179110-21-000984","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021000984/edgar.xml","form_type":"4"}},{"id":3284933,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-07T23:16:29.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the issuer through each such period."}],"balance_after":200000,"derivative":{"exercise_price":2.42,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001179110-20-001349","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/edgar.xml","form_type":"4"}},{"id":3364553,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-21T01:23:17.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":83750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person was granted a performance based option to purchase 83,750 shares of common stock on June 4, 2018. Thus,the exercise price of this option is $3.44 (the closing price of the issuer's common stock on Nasdaq the day of the grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted a performance based option to purchase 83,750 shares of common stock on June 4, 2018. Thus,the exercise price of this option is $3.44 (the closing price of the issuer's common stock on Nasdaq the day of the grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met."}],"balance_after":83750,"derivative":{"exercise_price":3.44,"expiration_date":"2028-06-04","underlying":"Common Stock","underlying_shares":83750},"source":{"system":"sec-edgar","filing":"0001179110-19-011948","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/edgar.xml","form_type":"4"}},{"id":3513827,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-24T00:21:09.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":3274,"price":2.1292,"value":6971.0008,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001179110-19-006608","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/edgar.xml","form_type":"4"}},{"id":3513826,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-24T00:21:09.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":46726,"price":2.131,"value":99573.106,"ownership":{"direct":true},"balance_after":46726,"source":{"system":"sec-edgar","filing":"0001179110-19-006608","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/edgar.xml","form_type":"4"}},{"id":3581873,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-22T23:28:17.000Z","date":"2019-03-20","kind":"grant","acquired":true,"shares":83750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 4, 2018, the reporting person was granted a performance based option to purchase 83,750 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met."}],"balance_after":83750,"derivative":{"exercise_price":3.44,"expiration_date":"2028-06-04","underlying":"Common Stock","underlying_shares":83750},"source":{"system":"sec-edgar","filing":"0001179110-19-004212","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/edgar.xml","form_type":"4"}},{"id":3686936,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-25T23:32:26.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019."}],"balance_after":162500,"derivative":{"exercise_price":2,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001179110-19-000934","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/edgar.xml","form_type":"4"}},{"id":3903713,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":2454,"kind":"person","name":"Schorno Dean L","position":1,"cik":"0001509688","reported_name":"Schorno Dean L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP &Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-06T23:59:50.000Z","date":"2018-06-04","kind":"grant","acquired":true,"shares":167500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the option vests one year from June 4, 2018 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months."}],"balance_after":167500,"derivative":{"exercise_price":3.44,"expiration_date":"2028-06-04","underlying":"Common Stock","underlying_shares":167500},"source":{"system":"sec-edgar","filing":"0001179110-18-008176","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/edgar.xml","form_type":"4"}}]}